| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE45198 | SALIX | Omeprazole solution and method for using same |
Jul, 2016
(7 years ago) | |
| US6699885 | SALIX | Substituted benzimidazole dosage forms and methods of using same |
Jul, 2016
(7 years ago) | |
| US6645988 | SALIX | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(7 years ago) | |
| US6489346 | SALIX | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(7 years ago) | |
| US5840737 | SALIX | Omeprazole solution and method for using same |
Jul, 2016
(7 years ago) | |
| US6780882 | SALIX | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(7 years ago) | |
| US7399772 | SALIX | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(7 years ago) | |
Zegerid is owned by Salix.
Zegerid contains Omeprazole; Sodium Bicarbonate.
Zegerid has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Zegerid are:
- USRE45198
- US6699885
- US6645988
- US6489346
- US5840737
- US6780882
- US7399772
Zegerid was authorised for market use on 15 June, 2004.
Zegerid is available in capsule;oral, for suspension;oral dosage forms.
Zegerid can be used as reduction of risk of upper gastrointestinal bleeding in critically ill patients, short term treatment of active benign gastric ulcer.
The generics of Zegerid are possible to be released after 16 July, 2016.
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 15 June, 2004
Treatment: Reduction of risk of upper gastrointestinal bleeding in critically ill patients; Short term treatment of active benign gastric ulcer
Dosage: FOR SUSPENSION;ORAL; CAPSULE;ORAL
ZEGERID family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6699885 | SANTARUS | Substituted benzimidazole dosage forms and methods of using same |
Jul, 2016
(7 years ago) | |
| US6489346 | SANTARUS | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(7 years ago) | |
| US6645988 | SANTARUS | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(7 years ago) | |
| US7399772 | SANTARUS | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(7 years ago) | |
Zegerid is owned by Santarus.
Zegerid contains Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate.
Zegerid has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zegerid are:
- US6699885
- US6489346
- US6645988
- US7399772
Zegerid was authorised for market use on 24 March, 2006.
Zegerid is available in tablet, chewable;oral dosage forms.
Zegerid can be used as short term treatment of active benign gastric ulcer, short-term treatment of active duodenal ulcer; treatment of heartburn and other symptoms associated with gerd; short-term treatment of erosive esophagitis; maintenance of healing of erosive esophagitis.
The generics of Zegerid are possible to be released after 16 July, 2016.
Drugs and Companies using MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 24 March, 2006
Treatment: Short term treatment of active benign gastric ulcer; Short-term treatment of active duodenal ulcer; Treatment of heartburn and other symptoms associated with gerd; Short-term treatment of erosive esop...
Dosage: TABLET, CHEWABLE;ORAL
ZEGERID family patents